Facing the Challenges in Transplantation
Executive Summary
The transplantation market has changed considerably since Novartis (via its predecessor, Sandoz) launched the then-revolutionary selective immunosuppressant cyclosporin in 1983. Nowadays, clinicians and patients have many more treatment options--thanks largely to enhanced understanding of immunology--and thus the trend is strongly towards individualized therapy. In response to this shift, Novartis has given up pursuing radically new approaches to treatment and is concentrating on developing a product for every class of drug now used to treat graft recipients.
You may also be interested in...
SangStat Bets on Focus vs. Size
Up against Novartis, the Swiss marketing giant that now owns the $1.3 billion market for cyclosporine, SangStat insists that its disease management approach to organ transplantation is the right model at the right time.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.